Charles G Glabe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2681440/publications.pdf

Version: 2024-02-01

49 papers	10,774 citations	159585 30 h-index	233421 45 g-index
52 all docs	52 docs citations	52 times ranked	11054 citing authors

#	Article	IF	Citations
1	Identification of amyloid antibodies for Alzheimer disease â€“ immunotherapy. Archives of Physiology and Biochemistry, 2022, 128, 1275-1282.	2.1	2
2	In vitro study of the mechanism of intraneuronal Î²-amyloid aggregation in Alzheimerâ€™s disease. Archives of Physiology and Biochemistry, 2022, 128, 732-739.	2.1	10
3	Conformation-dependent anti-AÎ² monoclonal antibody signatures of disease status and severity in urine of women with preeclampsia. Pregnancy Hypertension, 2022, 28, 51-59.	1.4	4
4	An â€œepitomicâ€•analysis of the specificity of conformation-dependent, anti-AÃŸ amyloid monoclonal antibodies. Journal of Biological Chemistry, 2021, 296, 100168.	3.4	9
5	Inefficient quality control of ribosome stalling during APP synthesis generates CAT-tailed species that precipitate hallmarks of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 169.	5.2	28
6	Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease. Journal of Biological Chemistry, 2020, 295, 10662-10676.	3.4	21
7	Intra- and extracellular Î²-amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus. Scientific Reports, 2019, 9, 15936.	3.3	12
8	Apolipoprotein E/Amyloid-Î² Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4. American Journal of Pathology, 2019, 189, 1621-1636.	3.8	35
9	Structure-based inhibitors of amyloid beta core suggest a common interface with tau. ELife, 2019, 8, .	6.0	81
10	Common fibrillar spines of amyloid-Î² and human islet amyloid polypeptide revealed by microelectron diffraction and structure-based inhibitors. Journal of Biological Chemistry, 2018, 293, 2888-2902.	3.4	50
11	Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 11.	10.8	260
12	Epitomic Characterization of the Specificity of the Anti-Amyloid AÎ² Monoclonal Antibodies 6E10 and 4G8. Journal of Alzheimer's Disease, 2018, 66, 1235-1244.	2.6	45
13	Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimerâ€™s pathology. Acta Neuropathologica, 2017, 134, 769-788.	7.7	85
14	Familial Alzheimerâ€™s Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-Î² Peptide. Journal of Biological Chemistry, 2017, 292, 3172-3185.	3.4	123
15	Atomic structures of fibrillar segments of hIAPP suggest tightly mated Î²-sheets are important for cytotoxicity. ELife, 2017, 6, .	6.0	95
16	The Anti-Amyloid-Î² Monoclonal Antibody 4G8 Recognizes a Generic Sequence-Independent Epitope Associated with Î±-Synuclein and Islet Amyloid Polypeptide Amyloid Fibrils. Journal of Alzheimer's Disease, 2016, 50, 517-525.	2.6	28
17	Effective anti-Alzheimer AÎ² therapy involves depletion of specific AÎ² oligomer subtypes. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e237.	6.0	39
18	Atomic-resolution structure of a disease-relevant AÎ²(1â€“42) amyloid fibril. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4976-84.	7.1	712

#	Article	IF	Citations
19	Structural differences between amyloid beta oligomers. Biochemical and Biophysical Research Communications, 2016, 477, 700-705.	2.1	65
20	Synaptic Amyloid-Î² Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. American Journal of Pathology, 2016, 186, 185-198.	3.8	94
21	Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and AÎ² pathology and modulates AÎ² oligomerization. Neurobiology of Disease, 2015, 82, 552-560.	4.4	48
22	Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Science Translational Medicine, 2014, 6, 245ra92.	12.4	181
23	Monoclonal Antibodies against AÎ²42 Fibrils Distinguish Multiple Aggregation State Polymorphisms in Vitro and in Alzheimer Disease Brain. Journal of Biological Chemistry, 2014, 289, 32131-32143.	3.4	103
24	Quantitative Imaging of Preamyloid Oligomers, a Novel Structural Abnormality, in Human Atrial Samples. Journal of Histochemistry and Cytochemistry, 2014, 62, 479-487.	2.5	13
25	Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiology of Disease, 2014, 71, 53-61.	4.4	85
26	Positron Emission Tomography Imaging of Fibrillar Parenchymal and Vascular Amyloid-Î² in TgCRND8 Mice. ACS Chemical Neuroscience, 2013, 4, 613-623.	3.5	21
27	Atomic View of a Toxic Amyloid Small Oligomer. Science, 2012, 335, 1228-1231.	12.6	518
28	Amyloid-Î² Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain. Journal of Biological Chemistry, 2011, 286, 22122-22130.	3.4	127
29	Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar AÎ² oligomers. Molecular Neurodegeneration, 2010, 5, 57.	10.8	135
30	Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer. Journal of Biological Chemistry, 2009, 284, 4230-4237.	3.4	307
31	Structural Classification of Toxic Amyloid Oligomers. Journal of Biological Chemistry, 2008, 283, 29639-29643.	3.4	716
32	Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Molecular Neurodegeneration, 2007, 2, 18.	10.8	655
33	Pore-Forming Proteins Share Structural and Functional Homology with Amyloid Oligomers. NeuroMolecular Medicine, 2007, 9, 270-275.	3.4	78
34	Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology, 2006, 66, S74-S78.	1.1	322
35	Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiology of Aging, 2006, 27, 570-575.	3.1	513
36	BIOMEDICINE: Avoiding Collateral Damage in Alzheimer's Disease Treatment. Science, 2006, 314, 602-603.	12.6	4

#	Article	IF	Citations
37	Conformation-dependent antibodies target diseases of protein misfolding. Trends in Biochemical Sciences, 2004, 29, 542-547.	7.5	154
38	Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis. Science, 2003, 300, 486-489.	12.6	3,748
39	Intracellular Mechanisms of Amyloid Accumulation and Pathogenesis in Alzheimer's Disease. Journal of Molecular Neuroscience, 2001, 17, 137-145.	2.3	205
40	Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation?. Nature Medicine, 2000, 6, 133-134.	30.7	34
41	Subtractive analysis of S. franciscanus and S. purpuratus ovary mRNA: what kinds of genes determine species-specificity?. Zygote, 1999, 8, S64-S64.	1.1	0
42	Improved synthesis and purification of Alzheimer's AÎ² 1â€“42 and analogs. International Journal of Peptide Research and Therapeutics, 1999, 6, 151-156.	0.1	0
43	Improved synthesis and purification of Alzheimer's AÎ² 1â€“42 and analogs. International Journal of Peptide Research and Therapeutics, 1999, 6, 151-156.	0.1	0
44	Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid A?1-42 pathogenesis. Journal of Neuroscience Research, 1998, 52, 691-698.	2.9	253
45	Amyloid ? protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. , 1998, 397, 139-147.		81
46	Amyloid Î² protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. Journal of Comparative Neurology, 1998, 397, 139-147.	1.6	3
47	Structureâ€Activity Analyses of Î²â€Amyloid Peptides: Contributions of the Î²25â€“35 Region to Aggregation and Neurotoxicity. Journal of Neurochemistry, 1995, 64, 253-265.	3.9	641
48	When Sperm Meets Egg: The Interaction of Bindin with Sulfated Fucans.. Trends in Glycoscience and Glycotechnology, 1991, 3, 406-413.	0.1	2
49	THE EFFECT OF SOLUBLE EGG JELLY ON THE FERTILIZABILITY OF ACID-DEJELLIED SEA URCHIN EGGS*. Development Growth and Differentiation, 1979, 21, 47-60.	1.5	28